Abstract
Objectives:
Use 2 weeks of chemoprevention with Celecoxib® (80mg /day) to screen malignant transformation of oral potentially malignant disorders (PMD).
Methods:
In a chemopreventive trial with 12 weeks of Celecoxib®, 133 testers out of 374 had persistent or growing tumors after 2 weeks of Celecoxib® and underwent excisional biopsy to define the tumor.
Results:
Pathology diagnosis of these 133 testers found squamous cell carcinoma in 46; verrucous carcinoma in 2; dysplasia in 21, including severe (2), moderate (5), and mild (14); verrucous hyperplasia in 60; and epithelial hyperplasia with ulcer in 4. Thus, chemoprevention screening identified 48 cancers and 2 severe dysplasias [(48+2)/133 = 37.6%] who needed definite surgical resection.
Conclusions:
Chemoprevention with 2 weeks of Celecoxib® can be a screening procedure to pick up oral PMD cases with possible malignant transformation that need definite surgical resection, and the incidence could be as high as 37.6%.
Get full access to this article
View all access options for this article.